Skip to main content
SpringerLink
Log in

Dementia

The rising global tide of cognitive impairment

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

A new study suggests that the application of uniform diagnostic criteria for mild cognitive impairment (MCI) substantially reduces variation in MCI prevalence estimates. Refinement and harmonization of clinical and research criteria are essential milestones towards improved testing of therapeutic interventions aimed at curbing the epidemic of MCI and dementia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Hypothetical staging model of sporadic Alzheimer disease (AD).

References

  1. Petersen, R. C. et al. Mild cognitive impairment: a concept in evolution. J. Intern. Med. 275, 214–228 (2014).

    Article  CAS  Google Scholar 

  2. Sachdev, P. S. et al. The prevalence of mild cognitive impairment in diverse geographical and ethnocultural regions: the COSMIC collaboration. PLoS ONE 10, e0142388 (2015).

    Article  Google Scholar 

  3. Sachdev, P. S. et al. COSMIC (Cohort Studies of Memory in an International Consortium): an international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groups. BMC Neurol. 13, 165 (2013).

    Article  Google Scholar 

  4. Prince, M. et al. The global prevalence of dementia: a systematic review and meta-analysis. Alzheimers Dement. 9, 63–75. e2 (2013).

    Article  Google Scholar 

  5. Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 13, 614–629 (2014).

    Article  Google Scholar 

  6. Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270–279 (2011).

    Article  Google Scholar 

  7. Schneider, L. S. The potential and limits for clinical trials for early Alzheimer's disease and some recommendations. J. Nutr. Health Aging 14, 295–298 (2010).

    Article  CAS  Google Scholar 

  8. Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K. & Brayne, C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 13, 788–794 (2014).

    Article  Google Scholar 

  9. Jagger, C. et al. A comparison of health expectancies over two decades in England: results of the Cognitive Function and Ageing Study I and II. Lancet 382, 1405–1452 (2015).

    Google Scholar 

  10. Solomon, A. et al. Advances in the prevention of Alzheimer's disease and dementia. J. Intern. Med. 275, 229–250 (2014).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

H.H. is supported by the AXA Research Fund, the Fondation Université Pierre et Marie Curie, the “Fondation pour la Recherche sur Alzheimer”, Paris, France, and the programme “Investissements d'avenir” (programme number ANR-10-IAIHU-06).

Author information

Authors and Affiliations

  1. Institute of Memory and Alzheimer's disease, Pierre and Marie Curie University, 47 Boulevard de l'Hôpital, Paris, 75651, Cedex 13, France

    Harald Hampel & Simone Lista

Authors
  1. Harald Hampel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simone Lista
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harald Hampel.

Ethics declarations

Competing interests

H.H. has received lecture honoraria from Biogen and Roche, research grants from Avid and Pfizer, travel funding from Axovant, Eli Lilly and company, GE Healthcare, Takeda and Zinfandel, consultancy fees from Anavex, Axovant, Cytox, GE Healthcare, Jung diagnostics, Takeda and Zinfandel, and participated in scientific advisory boards of Axovant, Cytox, GE Healthcare, Takeda and Zinfandel. He is co-inventor in (partly pending) patent submissions for which he has received no royalties. S.L. has received lecture honoraria from Roche.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hampel, H., Lista, S. The rising global tide of cognitive impairment. Nat Rev Neurol 12, 131–132 (2016). https://doi.org/10.1038/nrneurol.2015.250

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2015.250

  • Springer Nature Limited

This article is cited by

Search

Navigation